According to DelveInsight, over 80 major companies are actively engaged in developing more than 90 therapeutic candidates for the treatment of asthma.
Asthma Overview:
Asthma is a long-term respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, coughing, and chest tightness. It often begins in childhood and is frequently associated with other allergic conditions like eczema and hay fever. Asthma is a complex disease with various phenotypes, and genetic predisposition—especially a personal or family history of atopic disorders—is a major risk factor.
The condition affects roughly 15–20% of individuals in developed countries and 2–4% in less developed regions, with children being more commonly affected. About 40% of children experience wheezing at some point, and if this improves with beta-2 agonists, it may be diagnosed as asthma, even in the absence of abnormal lung function tests. Environmental factors such as exposure to tobacco smoke and airborne pollutants are strongly linked to the development and worsening of asthma.
Asthma involves reversible airway inflammation triggered by allergens or irritants, resulting in increased mucus production and airway resistance—especially noticeable during exhalation. Symptoms typically worsen at night and may be triggered by exercise, allergens, or cold air. Many people with asthma also have other allergic conditions, and some may experience nighttime coughing even when they feel fine during the day.
Request for a detailed insights report on Asthma pipeline insights
“Asthma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Asthma Therapeutics Market.
Key Takeaways from the Asthma Pipeline Report
DelveInsight’s Asthma pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
In September 2025, Kinaset Therapeutics shared two oral presentations and a late-breaking poster at the 2025 European Respiratory Society (ERS) Congress. These presentations highlighted the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), in treating patients with moderate to severe asthma as well as those with COPD.
In May 2025, GSK reported positive headline results from the phase III SWIFT-1 and SWIFT-2 clinical trials. These trials evaluated the efficacy and safety of depemokimab compared to a placebo in adults and adolescents with severe asthma associated with type 2 inflammation, as indicated by elevated blood eosinophil counts.
In April 2025, 25 abstracts on approved and investigational medicines were featured at the American Thoracic Society (ATS) International Conference. Among the highlights were data presentations from Sanofi’s immunology pipeline, including the first phase IIb data for rilzabrutinib in moderate to severe asthma.
Key Asthma companies such as GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others are evaluating new drugs for Asthma to improve the treatment landscape.
Promising Asthma pipeline therapies in various stages of development include GSK3511294, TQC2731, AZD4604, FB704A, ARO-RAGE, and others.
Asthma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Asthma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Asthma market.
Download our free sample page report on Asthma pipeline insights
Asthma Emerging Drugs
GSK3511294: GlaxoSmithKline
TQC2731: Chia Tai Tianqing Pharmaceutical Group
AZD4604: AstraZeneca
FB704A: Oneness Biotech Co., Ltd.
ARO-RAGE: Arrowhead Pharmaceuticals
Asthma Companies
Around 80 leading companies are actively involved in developing asthma therapies, with GlaxoSmithKline being a notable player, as its drug candidates for asthma are currently in the advanced Phase III stage of development.
DelveInsight’s report covers around 90+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Asthma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Asthma Therapies and Key Companies: Asthma Clinical Trials and advancements
Asthma Pipeline Therapeutic Assessment
• Asthma Assessment by Product Type
• Asthma By Stage
• Asthma Assessment by Route of Administration
• Asthma Assessment by Molecule Type
Download Asthma Sample report to know in detail about the Asthma treatment market @ Asthma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Asthma Current Treatment Patterns
4. Asthma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Asthma Late-Stage Products (Phase-III)
7. Asthma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Asthma Discontinued Products
13. Asthma Product Profiles
14. Asthma Key Companies
15. Asthma Key Products
16. Dormant and Discontinued Products
17. Asthma Unmet Needs
18. Asthma Future Perspectives
19. Asthma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Asthma Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
